Captor Capital Corp
F:NMVA
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (7.9), the stock would be worth €3.84 (1 400% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | €0.26 |
0%
|
| Industry Average | 7.9 | €3.84 |
+1 400%
|
| Country Average | 10.2 | €4.92 |
+1 820%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
C
|
Captor Capital Corp
F:NMVA
|
924k EUR | 0.5 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
976.4B USD | 31.9 | 47.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.4B USD | 15.3 | 22 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
294.6B CHF | 13.2 | 31.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.5B CHF | 14.1 | 22.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP | 17.2 | 31.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.5B USD | 10.5 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 344.9 | -74.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.7 | 10.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.2B USD | 7.4 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD | 7.3 | 17.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
Captor Capital Corp
Glance View
Captor Capital Corp. is an investment company. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-10-30. The firm cultivates, manufactures and distributes medical marijuana-based products to consumers through its brands and dispensary retail stores. The firm provides cannabis products, as well as other cannabis-based goods. The Company’s California joint venture portfolio consists two CHAI Cannabis Co. branded dispensaries, four One Plant branded dispensaries and three additional California cannabis retail licenses for stores under construction. CHAI Santa Cruz is a medical and cannabis dispensary in Santa Cruz County.
